Avenue Therapeutics, Inc. (ATXI)
OID · Healthcare · Biotechnology
$0.32
+6.67%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.1M
Shares Outstanding
3.3M
P/S (TTM)
0.8x
Exchange
OID
Currency
USD
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 1.4M | 0.00 | 0.00 | 0.00 |
| Operating Income | 297K | -724K | -955K | -714K |
| Net Income | 335K | -683K | -709K | -695K |
| Diluted EPS | $0.11 | $-0.21 | $nan | $-0.21 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.4M |
| Operating Income | -8.0M | -14.5M | -11.3M | -3.3M |
| Net Income | -3.6M | -10.4M | -11.7M | -2.9M |
| Diluted EPS | $-122.25 | $-73.48 | $-15.79 | $-0.93 |